Search company, investor...

Founded Year

2014

Stage

IPO | IPO

Total Raised

$108M

Date of IPO

10/9/2020

Market Cap

0.09B

Stock Price

2.44

About Spruce Biosciences

Spruce Biosciences (NASDAQ: SPRB) is a clinical-stage biopharmaceutical focused on developing new treatments for rare endocrine disorders. The company's mission is to develop meaningful therapies for patients with rare diseases affecting the hypothalamic-pituitary-adrenal (HPA) axis (the "stress pathway").

Headquarters Location

2001 Junipero Serra Blvd. Suite 640

San Francisco, California, 94104,

United States

414-294-1687

CB Insights
Looking for a leg up on competitive, customer and technology insights?
CB Insights puts confidence and clarity into your most strategic decisions.
See how. Join a demo.
Join a demo
Trusted by the world's smartest companies to:
  • Predict emerging trends
  • See competitors' playbooks
  • Stalk the smart money
  • Identify tomorrow's challengers
  • Spot growing industries
  • Kill analyst data work
Let's see how we can help you!
MicrosoftWalmartWells Fargo
You're one click away from the most comprehensive, unmatched analyst expertise in tech, in-depth private company data and a platform that brings it all together.
Click Now. Join a live demo
Join a demo

Spruce Biosciences Patents

Spruce Biosciences has filed 14 patents.

The 3 most popular patent topics include:

  • Pregnanes
  • Neuroendocrinology
  • Peptide hormones
patents chart

Application Date

Grant Date

Title

Related Topics

Status

4/13/2022

7/25/2023

G protein coupled receptors, Peptide hormones, Peptides, Neuroendocrinology, Neuropeptides

Grant

Application Date

4/13/2022

Grant Date

7/25/2023

Title

Related Topics

G protein coupled receptors, Peptide hormones, Peptides, Neuroendocrinology, Neuropeptides

Status

Grant

Latest Spruce Biosciences News

Spruce Bio gains after Neurocrine’s Phase 3 win for genetic disorder drug

Sep 12, 2023

solidcolours Neurocrine Biosciences ( NBIX ) said Tuesday its CRF1 antagonist crinecerfont for classic congenital adrenal hyperplasia (CAH) met the primary endpoint in a Phase 3 trial, rallying the shares of Spruce Biosciences (NASDAQ: SPRB ), a rival developer with a similar candidate in its pipeline. Citing topline data, Neurocrine ( NBIX ) said that crinecerfont reached the primary goal and key secondary endpoints in its CAHtalyst registrational trial. After the results, RBC Capital Markets argued that the CAHtalyst readout validated the potential of "CRF1 antagonism" in CAH. Spruce ( SPRB ) is advancing its CRF1 antagonist, tildacerfont, in CAHmelia-203. The Phase 2b placebo-controlled trial involving adults with classic CAH is expected to generate topline data in H2 2023. Last week, Leerink Partners upgraded SPRB to Outperform from Market Perform, expecting positive CAHmelia-203 data.

Spruce Biosciences Frequently Asked Questions (FAQ)

  • When was Spruce Biosciences founded?

    Spruce Biosciences was founded in 2014.

  • Where is Spruce Biosciences's headquarters?

    Spruce Biosciences's headquarters is located at 2001 Junipero Serra Blvd., San Francisco.

  • What is Spruce Biosciences's latest funding round?

    Spruce Biosciences's latest funding round is IPO.

  • How much did Spruce Biosciences raise?

    Spruce Biosciences raised a total of $108M.

  • Who are the investors of Spruce Biosciences?

    Investors of Spruce Biosciences include RiverVest Venture Partners, Novo Ventures, Aisling Capital, Abingworth, Sands Capital and 6 more.

CB Insights
Looking for a leg up on competitive, customer and technology insights?
CB Insights puts confidence and clarity into your most strategic decisions.
See how. Join a demo.
Join a demo
Trusted by the world's smartest companies to:
  • Predict emerging trends
  • See competitors' playbooks
  • Stalk the smart money
  • Identify tomorrow's challengers
  • Spot growing industries
  • Kill analyst data work
Let's see how we can help you!
MicrosoftWalmartWells Fargo

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Join a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.